Crystalline Oral Brexanolone Composition for Reliable Bioavailability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for central nervous system disorders, particularly depression, are inadequate due to slow onset of efficacy, high side effects, and poor oral bioavailability of brexanolone, necessitating hospitalization and inconvenient administration methods, which are not suitable for conditions like postpartum depression.

Innovation Solution

Development of oral brexanolone compositions in solid crystalline form with specific particle sizes and formulations to enhance absorption, achieving consistent pharmacokinetic profiles regardless of food intake, allowing for effective blood levels and rapid therapeutic effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If brexanolone is administered orally in conventional forms, then ease of operation is improved, but bioavailability and absorption rate deteriorate

Engineering Contradiction:

Improveease of administrationVSAvoidbioavailability

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent changes the physical and chemical parameters of brexanolone by converting it from conventional liquid or amorphous forms into specific solid crystalline forms (Polymorphs I, II, III, IV, V, and VI). This parameter change in molecular arrangement and crystal structure fundamentally alters the drug's dissolution and absorption characteristics, enabling reliable oral bioavailability while maintaining ease of administration as oral tablets or capsules.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite material systems by formulating brexanolone crystalline forms with specific excipients and carriers to create stable oral dosage forms. These composite formulations maintain the crystalline structure's beneficial properties while ensuring proper dissolution, absorption, and therapeutic effect delivery in the gastrointestinal tract.

Inventive Principle:

Principle #40Composite materials

2Reliability

If brexanolone is administered intravenously, then bioavailability is improved, but device complexity and ease of operation worsen due to hospitalization requirements

Engineering Contradiction:

ImprovebioavailabilityVSAvoidadministration system complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the administration process into a simple oral dosage form that can be taken at home, eliminating the need for complex intravenous infusion systems, hospitalization infrastructure, and specialized medical equipment. The crystalline formulation enables the drug to be delivered through simple oral tablets or capsules.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent replaces the mechanical intravenous infusion system with an oral administration system. Instead of requiring IV pumps, infusion bags, and hospital-based delivery mechanisms, the crystalline brexanolone formulation enables simple oral intake that achieves reliable bioavailability through its enhanced dissolution and absorption properties.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Ease of operation

If conventional antidepressants are used, then ease of operation is improved, but duration of action and therapeutic efficacy worsen due to slow onset

Engineering Contradiction:

Improveease of administrationVSAvoidonset of efficacy

Core Design Contradiction:

Ease of operationVSDuration of action of moving object

Solution Approach 1:

The patent changes the dissolution rate parameter by using specific crystalline forms of brexanolone that are engineered to dissolve and release the drug at optimized rates. This parameter change enables rapid absorption and quick onset of therapeutic effect, addressing the slow onset problem of conventional antidepressants while maintaining simple oral administration.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The solid crystalline brexanolone compositions provide rapid and effective treatment for CNS disorders with reduced side effects and improved bioavailability, enabling at-home administration and minimizing hospitalization time.

Implementation Method 1

The solid crystalline brexanolone compositions provide rapid and effective treatment for CNS disorders with reduced side effects and improved bioavailability

Methodology Applied

Scientific EffectDissolution:

Implementation Method 2

enhance absorption, achieving consistent pharmacokinetic profiles regardless of food intake

Methodology Applied

Scientific EffectAbsorption: Absorption (physical)

Data Source

PatentUS12576090B1Oral brexanolone compositions and methods of preparation and use

Publication Date: 2026.03.17 LIPOCINE INC

AI summary

Disclosed is a method and a brexanolone containing oral composition for treating CNS disorders such as depression. An embodiment of the invention comprises orally administering a brexanolone containing composition to a subject having a CNS disorder. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability and a predetermined ratio of bioavailability in a fed state administration relative to a fasted state administration.